Amer J Perinatol 2005; 22: 169-172 DOI: 10.1055/s-2005-864855
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Breakthrough Candida Infection in a Preterm Infant with Congenital Cutaneous Candida albicans Infection
Amos Adler1, Ita Litmanovitz1, Rivka Regev1, Shmuel Arnon1, Sophia Bauer1, Tzipora Dolfin1
1 Department of Neonatology, Meir Medical Center, Kfar-Saba; affiliated to the Tel-Aviv University-Sackler School of Medicine, Israel

ABSTRACT

Amphotericin B is the primary antifungal agent used for candida sepsis in neonates. Breakthrough candidemia was not reported in neonates during either amphotericin B or liposomal amphotericin B (AmBisome) treatment. We describe a case of a premature infant with congenital cutaneous candida infection, who had two episodes of breakthrough infection, from Candida albicans and Candida parapsilosis, while he was treated with amphotericin B and AmBisome, respectively. We discuss the pathogenesis of breakthrough infections, and the relevance of antifungal resistance and sensitivities testing.

KEYWORDS

Congenital cutaneous candidiasis - amphotericin B - fluconazole - antifungal susceptibilities testing